The Management of Spasticity in Adults
BMJ 349:g4737, Nair, K.P.S. & Marsden, J., 2014
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Explanation & Management of Neurological Disability
BMJ 294:1203-1205, Critchley,E.M.R.&Mitchell,J.D., 1987
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Vaccine-Preventable Infections and Immunization in Multiple Sclerosis
Neurol 93:584-594, Farez, M.F.,et al, 2019
A 34-Year-Old Man with Headache, Diploplia, and Hemiparesis
Neurol 86:e28, Lincoln, M.R.,et al, 2016
Responsibilities of Health Care PRofessionals in Counseling and Educating Patients with Incurable Neurological Diseases Regarding "Stem Cell Tourism"
JAMA Neurol 72:1342-1345, Bowman, M.,et al, 2015
Summary of Evidence-Based Guideline: Complementary and Alternative Medicine in Multiple Sclerosis
Neurol 82:1083-1092, Yadav, V.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
Disability in Multiple Sclerosis
Neurol 80:1018-1024, Kister, I.,et al, 2013
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Monosymptomatic Clinically Isolated Syndrome with Sudden Sensorineural Hearing Loss
The Neurologist 18:302-305, Anagnostouli, M.C.,et al, 2012
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Evidence-based Guideline: Clinical Evaluation and Treatment of Transverse Myelitis
Neurol 77:2128-2134, Scott, T.F.,et al, 2011
MRI Criteria for MS in Patients with Clinically Isolated Syndromes
Neurol 74:427-434, Montalban,X.,et al, 2010
Evidence Report: The Efficacy and Safety of Mitoxantrone (Novantrone) in the Treatment of Multiple Sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 74:1463-1470, Marriott,J.J., et al, 2010
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010
Pregnancy and Fetal Outcomes After Interferon-b Exposure in Multiple Sclerosis
Neurol 75:1794-1802, Amato,M.P.,et al, 2010
Dysexecutive Syndrome: Diagnostic Criteria and Validation Study
Ann Neurol 68:855-864, Godefroy,O.,et al, 2010
Tumefactive Multiple Sclerosis
www.medlink.com, JUne, Bunyan, R.F. and Lucchinetti, C.F., 2010
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Tempo of Disease. In Merritts Neurology. Signs and symptoms in neurologic diagnosis: Approach to the patient
, Rowland, L.P.,et al, 2009
Picturing Multiple Sclerosis: Conventional and Diffusion Tensor Imaging
Semin Neurol 28:453-466, Fox,R.J., 2008
An Approach to the Diagnosis of Acute Transverse Myelitis
Semin Neurol 28:105-120, Jacob, A.,et al, 2008
Sexual Function in Men and Women With Neurological Disorders
Lancet 369:512-525, Rees,P.M.,et al, 2007
Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report
Neurol 68:977-984, Goodin,D.S.,et al, 2007
Natalizumab for Multiple Sclerosis
NEJM 356:2622-2629, Ransohoff,R.M., 2007
Natalizumab (Tysabri) Treatment for Relapsing Multiple Sclerosis
The Neurologist 13:182-187, Johnson,K.P., 2007
Guidelines For Using Proton MR Spectroscopy in Multicenter Clinical MS Studies
Neurol 69:1942-1952, De Stefano,N.,et al, 2007
Standardized MR Imaging Protocol for Multiple Sclerosis:Consortium of MS Centers Consensus Guidelines
AJNR 27:455-461, Simon,J.H.,et al, 2006
Migraine and Cerebral White Matter Lesions
The Neurologist 11:19-29, Gladstone,J.P. &Dodick,D.W., 2005
Internuclear Ophthalmoplegia
Arch Neurol 62:714-717, Keane,J.R., 2005
Recommended Standard of Cerebrospial Fluid Analysis in the Diagnosis of Multiple Sclerosis, A Consensus Statement
Arch Neurol 62:865-870, Freedman,M.S.,et al, 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Acupuncture in Clinical Neurology
The Neurologist 9:137-148, Rabinstein,A.A. &Shulman,L.M., 2003
The Use of Mitoxantrone (Novantrone) for the Treatment of Multiple Sclerosis
Neurol 61:1332-1338, Goodin,D.S.,et al, 2003
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
Lesions of the Corpus Callosum: MR Imaging and Differential Considerations in Adults and Children
AJR 179:251-257, Bourekas,E.C.,et al, 2002
Interferon Beta but not Glatiramer Acetate Therapy Aggravates Headaches in MS
Neurol 59:636-639, Pollmann,W.,et al, 2002
Immunization and MS
Neurol 59:1837-1843, Rutschmann,O.T.,et al, 2002
Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
Ann Neurol 50:121-127, McDonald,W.I.,et al, 2001
Narcolepsy Associated with Other Central Nervous System Disorders
Neurol 57:539-541, Malik,S.,et al, 2001
Practice Parameter: The Usefulness of Evoked Potentials in Identifying Clinically Silent Lesions in Patients With Suspected Multiple Sclerosis (an Evidence-Based Review)
Neurol 54:1720-1725, Gronseth,G.S.&Ashman,E.J., 2000
Trauma Does Not Precipitate Multiple Sclerosis
Arch Neurol 57:1077-1078, Cook.S.D., 2000
Trauma to the Central Nervous System May Result in Formation or Enlargement of Multiple Sclerosis Plaques
Arch Neurol 57:1074-1076,1078, Poser,C.M., 2000
Diffusion-Weighted MR Imaging of the Brain
Radiology 217:331-345, Schaefer,P.W.,et al, 2000
The Relationship of MS to Physical Trauma and Psychological Stress, Report of the Therapeutics and Technology Assessment Subcommittee of the AAN
Neurol 52:1737-1745, Goodin,D.S.,et al, 1999
The Contribution of Magnetic Resonance Imaging to the Diagnosis of Multiple Sclerosis
Neurol 53:448-456, Fazekas,F.,et al, 1999